DEERFIELD, Ill. - Baxter International Inc. (NYSE:BAX) introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference, according to a company press ...

Baxter cut approximately 90 employees from a facility in Marion, North Carolina, that makes IV solutions for hospitals. The cuts, which took place in late January, account for about 3% of the ...

Data shared in collaboration with The University of Texas Medical Branch, representing an analysis of more than one million intravenous (IV) infusions using Baxter’s Spectrum IQ large volume infusion ...

Executives at healthcare company Baxter International Inc. misled investors about a medical device by “concealing systemic issues that put patients at the risk of severe injury and death,” according ...

Baxter International Inc. and its executives allegedly misled shareholders about systemic safety issues with its new IV fluid pump, which eventually led the company to halt sales, causing a stock drop ...

While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...

In the second quarter, Baxter turned in 1% operational sales growth and 28% adjusted EPS growth. Also, management reduced its guidance for 2025, including operational sales growth of 3% to 4% (down ...

Two people have died and 79 others have been seriously injured in potential association with a safety issue involving Baxter's Novum IQ large-volume infusion pumps. FDA said it is aware that Deerfield ...

Baxter International, a prominent healthcare and pharmaceutical manufacturer, reports that President Trump's tariffs will likely cost the company $60 million to $70 million this year. Baxter makes a ...

The company provided guidance for Q1 2025, projecting revenue of $19.2M to $19.4M, GAAP diluted EPS of $0.35 to $0.39, and non-GAAP diluted EPS of $0.39 to $0.43. For FY2025, revenue is expected to ...

Becton Dickinson (BD) medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the ...